15 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 15 of 15 clinical reviews.
Zepbound (tirzepatide) is FDA-approved for obesity, not diabetes, that role belongs to Mounjaro. Here is what the clinical trial data show, how physicians approach off-label prescribing, and what patients should know before starting.
Zepbound (tirzepatide) is FDA-approved for weight management, not diabetes. Learn about its off-label use for type 2 diabetes, the clinical evidence from SURPASS trials, and the monitoring your clinician should follow.
Zepbound (tirzepatide) is FDA-approved for obesity, not diabetes. This evidence summary covers the clinical trial data, off-label prescribing rationale, and how it compares to Mounjaro for blood-sugar control.
Zepbound (tirzepatide) is FDA-approved for weight management, not diabetes. Learn the evidence behind off-label use for type 2 diabetes, how it compares to Mounjaro, risks, and what clinicians consider before prescribing.
A clinical evidence review of tirzepatide (Zepbound) for heart failure, covering trial data from SUMMIT and STEP-HFpEF, FDA-approved indications, and what the research shows about cardiac outcomes.
Can Zepbound (tirzepatide) treat heart failure? Review the off-label evidence from SURMOUNT-HFpEF trials, FDA-approved indications, cardiovascular risks, and what clinicians consider before prescribing.
Tirzepatide (Zepbound) is being studied for heart failure with preserved ejection fraction. Learn what the SUMMIT trial showed, how off-label dosing works, and when a clinician might consider it.
Tirzepatide (Zepbound) is not FDA-approved for heart failure. Trial evidence in HFpEF with obesity shows symptom and functional improvement, but not proven reductions in hospitalization or death. Here is what the evidence supports, what remains unproven, and what monitoring off-label use requires.
Tirzepatide (Zepbound) is not FDA-approved for PCOS, but emerging trial data suggest meaningful improvements in ovulation, insulin resistance, and androgen levels. Here's what clinicians and patients need to know about off-label use.
A detailed clinical review of tirzepatide (Zepbound) for polycystic ovary syndrome: off-label status, trial data, mechanism, dosing, risks, and guideline context.
Tirzepatide (Zepbound) is used off-label for PCOS to improve insulin resistance, lower androgens, and restore ovulation. Learn what the evidence shows, how dosing works, and what to expect.
Tirzepatide (Zepbound) is not FDA-approved for PCOS, but clinicians are using it off-label based on its weight-loss and insulin-sensitizing effects. Here is what is established, what is plausible but unproven, and what monitoring is reasonable before and during treatment.
Clinical evidence for using Zepbound (tirzepatide) off-label to treat obstructive sleep apnea, including SURMOUNT-OSA trial data, AHI reductions, and prescribing considerations.
Tirzepatide (Zepbound) shows strong clinical evidence for reducing sleep apnea severity. Learn about its off-label status, the SURMOUNT-OSA trial data, dosing protocols, and what to discuss with your physician.
SURMOUNT-OSA trial data show tirzepatide cut AHI by about 50% and body weight by 18-20% over 52 weeks. See dosing and monitoring steps used off-label.